請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/44121
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 潘子明(Tzu-Ming Pan) | |
dc.contributor.author | Kai-Chien Lee | en |
dc.contributor.author | 李楷謙 | zh_TW |
dc.date.accessioned | 2021-06-15T02:40:53Z | - |
dc.date.available | 2010-08-19 | |
dc.date.copyright | 2009-08-19 | |
dc.date.issued | 2009 | |
dc.date.submitted | 2009-08-11 | |
dc.identifier.citation | BLAST (http://blast.ncbi.nlm.nih.gov/Blast/)
國家衛生研究院實驗動物資訊網 (http://las.nhri.org.tw/) 行政院衛生署。2008。基因改造食品之安全性評估方法。 行政院衛生署。2003。健康食品之胃腸功能改善評估方法。衛署食字第 0920401629號公告修正。 古庭維。2008。納豆菌液態培養生產枯草桿菌素 NAT 最適條件之探討及其應用於乳酸球菌表現。國立臺灣大學微生物與生化學研究所碩士學位論文。台北。 李麗鳳。2004。蛋白質表現系統簡介。化工資訊與商情。16: 34-41。 沈孝宙。2008。轉基因之爭。化學工業出版社,北京,中國。 宋思揚、樓士林。2008。生物技術概論。科學出版社,北京,中國。 許元勳。2005。納豆菌發酵製品介紹及國內研發現況。農業生技產業季刊。3: 45-52。 商惠芳、劉珍芳、曾金章、王正怡、李玲玟、葉必立、高信義、鍾美玉、呂秀介、謝明哲。2000。優酪乳對人體腸道細菌相及血液生化分析之影響。中華民國營養學會雜誌。25: 159-169。 張剛。2007。乳酸細菌:基礎、技術和應用。化學工業出版社,北京,中國。 鄒克琴。2009。基因工程原理和技術。浙江大學出版社,杭州,中國。 霍禮嘉、顧紅雅、胡蘋、陳章良。2004。現代生物技術。高等教育出版社,北京,中國。 楊媛絢。1998。原生保健性菌種與益助性生質之應用。食品工業。30: 11-22。 程金燕。2000。由改善腸胃道的功能來探討機能性食品的功效。科學與技術。32(6): 48-57。 顏文俊。1991。腸內菌群與人體健康。食品工業。23(9):46-52。 郭本恒。2004。益生菌。化學工業出版社,北京,中國。 蔡英傑。1998。乳酸菌應用綜論。生物產業。9: 258-264。 蘇遠志。2003。納豆菌代謝產物的開發與應用。生物產業。14: 117-130。 Arai, K., Kamata, T., Uchikoba, H., Fushinobu, S., Matsuzawa, H. and Taguchi, H. 2001. Some Lactobacillus L-lactate dehydrogenases exhibit comparable catalytic activities for pyruvate and oxaloacetate. J. Bacteriol. 183(1): 397-400. Arunachalam, K. D. 1999. Role of bifidobacteria in nutrition, medicine and technology. Nutr Res 19: 1559-1597. Astwood, J. D. and Fuchs, R. L. 1996.Allergenicity of foods derived from transgenic plants. Monogr. Allergy 32: 105-120. Bahey-El-Din, M., Griffin, B. T. and Gahan, C. G. M. 2008. Nisin inducible production of listeriolysin O in Lactococcus lactis NZ9000. Microb. Cell. Fact. 24: 1-10. Benno, Y., Sawada, K. and Mitsuoka, T., 1984. The intestinal microflora of infants: composition of fecal flora in breast-fed and bottle-fed infants. Microbiol. Immunol. 28: 975-986. Collins, M. D. and Gibson, G. R. 1999. Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology and gut. Am. J. Clin. Nutrt. 69: 1052S-1057S. Doyle, M. P. and Erickson, M. C. 2006. Closing the door on the fecal coliform assay. Microbe. 1: 4: 162-163. FAO/WHO. 2001. Report of a Joint FAO/ WHO Expert consultation on allergenicity of foods derived from biotechnology. Evaluation of allergenicity of genetically modified foods. p. 22-25. Fooks, L. J., Fuller, R., and Gibson, G. R. 1999. Prebiotics, probiotics and human gut microbiology. Int. Dairy J. 9: 53-61. Fukushima, Y., Li, S. T., Hara, H., Terada, A. and mitsuoka, T. 1997. Effect of follow-up formula containing Bifidobacteria (NAN BF) on fecal flora and fecal metabolites in healthy children. Biosci. Microflora 16: 65-72. Fujita, M., Nomura, K., Hong, K., Ito, Y., Asada, A. and Nishimuro, S. 1993. Purification and characterization of a strong fibrinolytic enzyme (nattokinase) in the vegetable cheese natto, a popular soybean fermented food in Japan. Biochem. Biophys. Res. Commun. 197: 1340-1347. Fujita, M., Hong, K., Ito, Y., Misawa, S., Takeuchi, N., Kariya, K. and Nishimuro, S. 1995. Transport of nattokinase across the rat intestinal tract. Biol. Pharm. Bull. 18: 1194-1196. Fuller, R. 1989. Probiotics in man and animals. J. Appl. Bacteriol. 66: 365-378. Gibson, G. R. and Fuller, R. 2000. Aspects of in vitro and in vivo research approaches directed toward identifying probiotics and prebiotics for human use. J. Nutr. 130: 391S-395S. Giknis, M. L. A. and Clifford, C. B. 2008. Clinical laboratory parameters for Crl: WI(Han) Rats. Charles River Labortories. Henderson, A. L., Cao, W. W., Wang, R. F., Lu, M. H. and Cerniglia, C. E. 1998. The effect of food restriction on the composition of intestinal microflora in rats. Exp. Gerontol. 33: 239-247. Hiromi, K., Ohmomo, S., Nomura, M., Kobayashi, M., Mizumahi, K. and Okamoto, T. 2008. Interference of in vitro and in vivo growth of several intestinal bacteria by Lactococcus strains. J. Microbiol. Biotechnol. 18: 1286–1289. Holzapfel, W. H., Haberer, P., Snel, J., Schillinger, U., and Huis in't Veld, J. H. J. 1998. Overview of gut flora and probiotics. Int. J. Food Microbiol. 41: 85-101. Hsu, H.C., Hsu, C.I., Lin, R.H., Kao, C.L. and Lin, J.Y. 1997. Fip-vvo, a new fungal immunomodulatory protein isolated from Volvariella volvacea. Biochem. J. 323: 557-565 Hummel, A. S., Hertel, C. W., Holzapfel, H. and Franz, C. M. A. P. 2007. Characterisation and transfer of antibiotic resistance genes from enterococci isolated from food. Syst. Appl. Microbiol. 30: 1-7. Ishibashi, N. and Yamazaki, S. 2001. Probiotics and safety. Am. J. Clin. Nutr. 73: 465-470. Kamata, H., Yamagata, T., Nakamura, T., Nakajima, T., Oda, K., Murao, S., Ichishima, E. 1989. Characterization of the complex between α2-macroglobulin and a serine proteinase from Bacillus natto. Agric. Biol. Chem. 53: 2695-2702. Klare, I., Konstabel, C., Werner, G., Huys, G., Vankerckhoven, V., Kahlmeter, G., Hildebrandt, B., Mu‥ller-Bertling, S., Witte, W. and Goossens, H. 2007. Antimicrobial susceptibilities of Lactobacillus, Pediococcus and Lactococcus human isolates and cultures intended for probiotic or nutritional use. J. Antimicrob. Chemother. 59: 900-912. Kimber, I., Betts, C. J. and Dearman, R. J. 2003. Assessment of the allergenic potential of proteins. Toxicol. Lett. 140-141: 297-/302. Ladics, G.S. 2008. Current codex guidelines for assessment of potential protein allergenicity. Food. Chem. Toxicol. 46: 520-523. LeBlanc, J. G., Burgess, C., Sesma, F., Savoy de Giori, G. and van Sinderen, D. 2005. Ingestion of milk fermented by genetically modified Lactococcus lactis improves the riboflavin status of deficient rats. J. Dairy Sci. 88: 3435–3442. Lidbeck, A. and Nord, C. E. 1991. Lactobacilli in relation to human ecology and antimicrobial therapy. Int. J. Tiss. Reac. 13: 115-122. Liong, M. 2008. Safety of probiotics: translocation and infection. Nutr. Rev. 66: 192–202. Macfarlane, G. T. and Macfarlane, S. 1997. Human colocic microbiota: ecology, physiology and metabolic potential of intestinal bacteria. Scand. J. Gastroenterol. 32 suppl. 222: 3-9. Marshall, V. M. 1991. Gut-derived organisms for milk fermentations. J. Chem. Technol. Biotechnol. 51: 548-553. Mary, L.A. and Charles B.C. 2006. Clinical laboratory parameters for Crl: CD (SD) rats. Charles River Labortories. Mierau, I. and Kleerebezem, M. 2005. 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl. Microbiol. Biotechnol. 68: 705–717. Miglioli, P. A., Allerberger, F., Calabr`o, G. B. and Gaion, R. M. 2001. Effects of daily oral administration of rifaximin and neomycin on faecal aerobic flora in rats. Pharmacol. Res. 44: 373-375. Mitsuoka, T. 1990. Bifidobacteria and their role in human health. J. Ind. Microbiol. 6: 263-268. Mitsuoka, T. 1996. Intestinal flora and human health. Asia Pacific J. Clin. Nutr. 5: 2-9。 Morishita, Y., Nagasawa, K., Nakano, N. and Shiromizu, K. 1988. Bacterial overgrowth in the jejunum of ICR mice and Wistar rats orally administered with a single lethal dose of fusarenon-X, a trichothecene mycotoxin. J. Appl. Bacteriol. 66: 263-270. Murtach, G. J, Dumoulin, M., Archer, D. B. and Alcocer M. J. 2002. Stability of recombinant 2S albumin allergens in vitro. Biochem. Soc. Trans. 30: 913–915. Naidu, A. S., Bidlack, W. R., and Clemens, R. A. 1999. Probiotic spectra of lactic acid bacteria (LAB). Crit. Rev. Food Sci. Nutr. 39: 13-126. Nord, C. E., Lidbeck, A., Orrhage, K., and Sjostedt, S. 1997. Oral supplementation with lactic acid-producing bacteria during intake of clindamycin. Clin. Microbiol. Infect. 3: 124-132. Ofori-Anti, A.O., Ariyarathna, H., Chen, L., Lee, H.L., Pramod, S.N. and Goodman, R. E. 2008. Establishing objective detection limits for the pepsin digestion assay used in the assessment of genetically modified foods. Regul. Toxicol. Pharmacol. 52: 94-103. Rasic JL. and Kurmann JA. 1983. Bifidobacteria and their role. Microbiological, nutritional-physiological, medical and technological aspects and bibliography. Experientia. Suppl. 39:1-295. Roberfroid, M. B. 2001. Prebiotics: preferential substrates for specific germs? Am. J. Clin. Nutr. 73: 406S-409S. Subbian, E., Yabuta, Y. and Shinde, U. P. 2005. Folding pathway mediated by an intramolecular chaperone: intrinsically unstructured propeptide modulated stochastic activation of subtilisin. J. Mol. Biol. 347: 367-383. Sumi, H., Hamada, H., Tsushima, H., Mihara, H., Muraki, H. 1987. A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese natto; a typical and popular soybean food in the Japanese diet. Experientia 43: 1110-1111. Sumi, H., Hamada, H., Mihara, H., Nakanishi, K. and Hiratani, H. 1989. Fibrinolytic effect of the Japanese traditional food “Natto” (Nattokinase). Throm. Haemos. 62: 549. Sumi, H., Hamada, H., Nakanishi, K., Hiratani, H. 1990. Enhancement of the fibrinolytic activity in plasma by oral administration of nattokinase. Acta. Haematol. 84: 139-143. Suzuki Y., Kondo K., Ichise H., Tsukamoto Y., Urano T. and Umemura K. 2003. Dietary supplementation with fermented soybeans suppresses intimal thickening. Nutrition 19: 261-264. Tannock, G. W. 1995. Microecology of the gastrointestinal tract inrelation to lactic acid bacteria. Int. Dairy J. 5: 1059-1070. Teuber, M., Meile, L. and Schwarz, F. 1999. Acquired antibiotic resistance in lactic acid bacteria from food. Antonie Van Leeuwenhoek. 76: 115–137. Thomas, K., Aalbers, M., Bannon, G. A., Bartels, M., Dearman, R. J., Esdaile, D. J., Fu, T. J., Glatt, C. M., Hadfield, N., Hatzos, C., Hefle, S. L., Heylings, J. R., Goodman, R. E., Henry, B., Herouet, C., Holsapple, M., Ladics, G. S., Landry, T. D., MacIntosh, S. C., Rice, E. A., Privalle, L. S., Steiner, H. Y., Teshima, R., Van Ree, R., Woolhiser, M. and Zawodny, J. 2004. A multi-laboratory evaluation of a common in vitro pepsin digestion assay protocol used in assessing the safety of novel protein. Regul. Toxicol. Pharmacol. 39: 87–98. Urano, T., Ihara, H., Umemura, K., Suzuki, Y., Oike, M., Akita, S., Tsukamoto, Y., Suzuki, I., Takada, A. 2001. The profibrinolytic enzyme subtilisin NAT purified from Bacillus subtilis cleaves and inactivates plasminogen activator inhibitor type I. J. Biol. Chem. 276: 24690-24696. Usman, B. and Hosono, A. 2001. Hypocholesterolemic effect of Lactobacillus gasseri SBT0270 in rats fed a cholesterol-enriched diet. J. Dairy Res. 68: 617-624. Vesterlund, S., Vankerckhoven, V., Saxelin, M., Goossens, H., Salminen, S. and Ouwehand, A. C. 2007. Safety assessment of Lactobacillus strains: Presence of putative risk factors in faecal, blood and probiotic isolates. Int. J. Food Microbiol. 116: 325–331. Waaij, D. and Nord, C. E. 2000. Development and persistence of multi-resistance to antibiotics in bacteria; an analysis and a new approach to this urgent problem. Int. J. Antimicrob. Agents. 16: 191-197. Wu, J., Zhang, W., Xie, B., Wu, M., Tong, X., Kalpoe, J. and Zhang, D. 2009. Detection and toxin typing of Clostridium perfringens in formalin-fixed, paraffin-embedded tissue samples by PCR. J. Clin. Microbiol. 47: 807-810. Yabuta, Y., Subbian, E., Oiry, C. and Shinde, U. 2003. Folding pathway mediated by an intramolecular chaperone. A functional peptide chaperone designed using sequence databases. J. Bacterol. 160: 15-21. Zhou, X. X., Li, W. F., Ma, G. X. and Pan, Y. J. 2006. The nisin-controlled gene expression system: Construction, application and improvements. Biotechnol. Adv. 24: 285-295. Zoppi, G., Cinquetti, M., Benini, A., Bonamini, E. and Minelli, E. B. 2001. Modulation of the intestinal ecosystem by probiotics and lactulose in children during treatment with ceftriaxone. Curr. Ther. Res. Clin. Exp. 62:418-435. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/44121 | - |
dc.description.abstract | 本研究為評估基因改造乳酸菌之安全性,使用基因改造乳酸菌 Lactococcus lactis NZ9000/pNZPNK,以三種實驗進行分析:一、抗藥性基因檢測:以基因改造乳酸菌所攜帶之質體及非基改乳酸菌染色體為模板進行聚合酶鏈反應 (polymerase chain reaction, PCR),於質體增幅所得抗藥性基因序列其大小正確,且經定序、比對後顯示為原本之抗藥性基因;非基改乳酸菌染色體則無抗藥性基因之存在。二、將非基因改造乳酸菌及基因改造乳酸菌破菌後分為可溶性蛋白質及細胞碎片兩部分,於基因改造乳酸菌之細胞碎片中以 SDS-PAGE 觀察到納豆激酶 (nattokinase),顯示乳酸鏈球菌素 (nisin) 可成功誘導基改乳酸菌胞內生產納豆激酶;對所得可溶性蛋白質及細胞碎片進行胃蛋白酶水解,以 SDS-PAGE 分析發現所有蛋白質皆無法抵抗胃蛋白酶之水解;以具納豆激酶專一性之抗體對水解前後片段進行西方墨點法分析,於未水解片段中觀察到納豆激酶但已水解者則否,顯示所表現納豆激酶被降解。三、參考衛生署公告之腸道菌相改善評估辦法,於實驗中檢測大鼠腸道中產氣莢膜梭菌 (Clostridium perfringens)、雙歧桿菌 (Bifodobacterium) 兩株指標菌;其中 C. perfringens 若減少或不變而 Bifodobacterium 增加,則可認定受試物質有改善腸道菌相之功能。此外,本研究檢測腸道中常見之菌叢包括大腸桿菌群 (coliform bacteria) 及乳酸桿菌 (Lactobacillus),觀察乳酸菌與重要腸道菌之互動,並檢測所餵食之基因改造乳酸菌以評估其存活力。實驗結果顯示,於所有組別中 C. perfringens 皆無法被偵測,Bifidobacterium 在餵食乳酸菌的數個組別,於四週時有顯著的增加 (p<0.05),六週時則未出現此現象。大腸桿菌群於四週時各組間並無顯著差異,六週時餵食乳酸菌組則普遍較控制組低 (p<0.05);乳酸桿菌於四週時沒有差異,六週時餵食乳酸菌之組別明顯增加 (p<0.05)。以上菌相變化顯示餵食基因改造乳酸菌或非基因改造乳酸菌,對腸道菌相並沒有不良的影響。於腸道菌相評估實驗後收集相關檢體進行血清生化學及血液學檢查,結果顯示肝腎功能指標、血糖、血脂、電解質及血球組成,各組沒有顯著差異。細菌位移試驗對肝臟、脾臟、腎臟及血液進行檢測,於所有樣本中都未觀察到轉移現象。總結實驗結果,餵食基因改造乳酸菌 L. lactis NZ9000/pNZPNK 對大鼠之腸道菌相、體重、血清生化值及血液組成並無不良影響,於大鼠模型中能安全使用。未來若有類似的基因改造微生物,本實驗架構可為其安全性評估之參考。 | zh_TW |
dc.description.abstract | The genetically modified microorganism (GMM) is derived from the techniques of modern biotechnology which is purposed to use in food and pharmaceutical industry. However, safety assessment for the potential risk of GMM must be considered. We introduced detection of antibiotic resistance genes, pepsin digestion assay and evaluation of intestinal microflora to assess the safety of GMM. The samples applied in this study were genetically modified lactic acid bacteria Lactococcus lactis NZ9000/pNZPNK and the host strain L. lactis NZ9000. Polymerase chain reaction (PCR) analysis of GM strain resulted in correct sequence of antibiotic resistance gene cat, indicating that antibiotic resistance gene remained unchanged after genetic engineering. By applying GM strain and host strain to pepsin digestion assay, the protein fractions of both soluble protein fractions and cell debris were degraded completely and rapidly. The produced nattokinase was undetectable after digestion with western blotting analysis. To assess the interaction between GM strain and intestinal microflora, Wistar rats received GM strain and host strain. Several important intestinal bacteria were counted. A significant increase in the count of Bifidobacterium in rat feces was observed after fed both GM and host strains for 4 weeks, but the count of Bifidobacterium had showed no significant change after fed GM and host strains for 6 weeks and the count of Clostridium perfringens in rat feces had no difference in all groups. These results suggest that Lactococcus lactis NZ9000/pNZPNK has low allergenicity and likely to be safe for human consumption. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T02:40:53Z (GMT). No. of bitstreams: 1 ntu-98-R96b47107-1.pdf: 3985627 bytes, checksum: f01095254482c267654c6466828ce75f (MD5) Previous issue date: 2009 | en |
dc.description.tableofcontents | 中文摘要………………………………………………………………………………Ⅰ
Abstract………………………………………………………………………………....Ⅳ 目錄……………….....................................................................................................Ⅴ 圖目錄………………………………………………………………………………….Ⅷ 表目錄…………………………………………………………………………………X 前言………………………………………………………………………………...……1 文獻回顧………………………………………………………………………………2 1.1 基因改造生物……………………………………………………………………2 1.1.1 基因改造微生物………………………………………………………………..2 1.1.2 基因改造微生物之用途………………………………………………………3 1.1.3 基因改造微生物潛在問題……………………………………………………5 1.1.4 基因改造微生物相關規範……………………………………………………7 1.2 腸道菌相………………………………………………………………………9 1.2.1 人體腸道菌相分佈……………………………………………………………9 1.2.2 腸道菌相對宿主之影響………………………………………………………10 1.2.3 腸道內菌群存在之重要性……………………………………………………11 1.2.4 影響腸道菌相之因素………………………………………………………11 1.2.5 調整腸道菌群對健康之幫助………………………………………………12 1.2.6 腸道菌相改善評估辦法……………………………………………………12 1.3 乳酸菌……………………………………………………………………………14 1.3.1 乳酸菌之定義………………………………………………………………14 1.3.2 乳酸菌之應用………………………………………………………………14 1.3.3 乳酸菌遺傳工程於工業上應用之價值……………………………………14 1.3.4乳酸菌表現系統……………………………………………………………15 1.4 納豆激酶………………………………………………………………………17 1.4.1 納豆激酶之發現……………………………………………………………17 1.4.2 納豆激酶之特性……………………………………………………………17 1.4.3 納豆激酶之保健功能………………………………………………………17 1.4.4 納豆激酶溶解血纖維之機制………………………………………………18 材料與方法…………………………………………………………………………20 2.1 實驗材料………………………………………………………………………20 2.1.1 藥品試劑………………………………………………………………………20 2.1.2 儀器設備…………………………………………………………………21 2.1.3 菌株及質體…………………………………………………………………22 2.1.4 培養基…………………………………………………………………………24 2.1.4.1 GM17 medium……………………………………………………………24 2.1.4.2 BIM-25 medium…………………………………………………………24 2.1.4.3 3MTM PetrifilmTM E. coli and Coliform Count Plate………………………25 2.1.4.4 TSC medium………………………………………………………………25 2.1.4.5 MRS medium…………………………………………………………………27 2.1.4.6 厭氧稀釋液……………………………………………………………………27 2.2 實驗方法………………………………………………………………………28 2.2.1 體外實驗方法…………………………………………………………………28 2.2.1.1 基因改造微生物之抗藥性基因檢測……………………………………28 2.2.1.1.1 質體之抽取……………………………………………………………30 2.2.1.1.2 染色體之抽取…………………………………………………………30 2.2.1.1.3 聚合酶鏈反應引子及條件……………………………………………31 2.2.1.2 蛋白質濃度偵測…………………………………………………………31 2.2.1.3 破菌方法…………………………………………………………………34 2.2.1.4 胃蛋白酶水解試驗………………………………………………………34 2.2.1.5 蛋白質電泳………………………………………………………………34 2.2.1.6 蛋白質轉印………………………………………………………………36 2.2.1.7 西方墨點法………………………………………………………………37 2.2.1.8 產氣莢膜梭菌之分生鑑定………………………………………………37 2.2.2 動物實驗方法…………………………………………………………………39 2.2.2.1 動物飼養與分組………………………………………………………….39 2.2.2.2 餵食劑量………………………………………………………………….39 2.2.2.3 動物犧牲法……………………………………………………………………41 2.2.2.4 腸道菌相評估…………………………………………………………………41 2.2.2.5 血清生化值及血液學檢查…………………………………………………42 2.2.2.6 細菌位移試驗……………………………………………………………42 2.2.2.7 統計分析………………………………………………………………………43 結果與討論…………………………………………………………………………44 3.1 基因改造微生物之抗藥性基因檢測…………………………………………44 3.2 胃蛋白酶水解試驗……………………………………………………………51 3.3 動物實驗………………………………………………………………………67 3.3.1 實驗動物體重與攝食量之變化……………………………………………67 3.3.2 腸道菌相評估………………………………………………………………67 3.3.3 實驗動物之血清生化值……………………………………………………81 3.3.4 實驗動物之血液學分析……………………………………………………81 3.3.5 細菌位移試驗………………………………………………………………81 3.3.6 產氣莢膜梭菌分生檢驗……………………………………………………81 結論…………………………………………………………………………………91 參考文獻……………………………………………………………………………92 | |
dc.language.iso | zh-TW | |
dc.title | 基因改造乳酸菌 Lactococcus lactis NZ9000/pNZPNK
安全性評估 | zh_TW |
dc.title | Safety assessment of genetically modified lactic acid bacteria Lactococcus lactis NZ9000/pNZPNK | en |
dc.type | Thesis | |
dc.date.schoolyear | 97-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 黃健雄(Jan-Hsiung Huang) | |
dc.contributor.oralexamcommittee | 蘇遠志(Yuan-Chi Su),游若?(Roch-Chui Yu),蔡宗佑(Tsung-Yu Tsai) | |
dc.subject.keyword | 基因改造微生物,腸道菌相,安全性評估,乳酸菌, | zh_TW |
dc.subject.keyword | Genetically modified microorganism (GMM),intestinal microflora,safety assessment,lactic acid bacteria, | en |
dc.relation.page | 97 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2009-08-11 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 微生物與生化學研究所 | zh_TW |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-98-1.pdf 目前未授權公開取用 | 3.89 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。